NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients
.

Abstract

OBJECTIVES:

Skin rash is a common adverse event induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here, we aimed to predict factors that reduce EGFR-TKI-related skin rash.

MATERIALS AND METHODS:

We conducted a single-center, retrospective study to predict factors that reduce skin rash in patients undergoing treatment for non-small cell lung cancer (NSCLC) with EGFR-TKIs using Cox proportional hazards model.

RESULTS:

Cox proportional hazard analysis revealed that coadministration of non-steroidal anti-inflammatory drug (NSAID) had protective effects against rash. Steroid coadministration showed a trend to being effective in reducing rash.

CONCLUSION:

NSAIDs may be useful in preventing EGFR-TKI-related skin rash.
.

• Authors: Yohei Iimura, Hitoshi Shimomura, Takeo Yasu, Keiko Imanaka, Ryuichi Ogawa, Akihiko Ito, Kenichi Suzuki, Gaku Yamaguchi, Norihisa Kawasaki, Chimori Konaka
• Journal: International journal of clinical pharmacology and therapeutics (Int J Clin Pharmacol Ther) Vol. 56 Issue 11 Pg. 551-554 (Nov 2018) ISSN: 0946-1965 [Print] Germany
• PMID: 30232957 (Publication Type: Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Antineoplastic Agents
• Protein Kinase Inhibitors
• EGFR protein, human
• ErbB Receptors
• Protein-Tyrosine Kinases

Topics

• Adolescent
• Aged
• Aged, 80 and over
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Antineoplastic Agents (adverse effects)
• Carcinoma, Non-Small-Cell Lung (complications, drug therapy)
• Drug Eruptions (prevention & control)
• ErbB Receptors (antagonists & inhibitors)
• Female
• Humans
• Lung Neoplasms (complications, drug therapy)
• Male
• Middle Aged
• Protein Kinase Inhibitors (adverse effects)
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Retrospective Studies